BILL ANALYSIS

HR4056

NEUTRAL

RAMP Act

HR4056 (RAMP Act) has been assessed with a neutral outlook for investors. The primary sectors impacted are Healthcare and Finance. View the full bill text on Congress.gov.

neutral

Market Sentiment

3/10

Impact Score

Sectors Impacted

Key Takeaways for Investors

RAMP Act is procedural/early-stage; no near-term market impact for $UNH, $CI, $HUM.

Real beneficiaries are auto/liability/workers' comp insurers (not among the named tickers).

Group health insurers retain full MSP private lawsuit exposure under the bill's language.

$UNH, $CI, $HUM recent price moves (30-day gains of 35%, 8%, 39%) are uncorrelated with this bill.

How HR4056 Affects the Market

For $UNH, , and , the RAMP Act is a non-event in the near term. Their 30-day price moves are substantial and likely reflect other catalysts such as Medicare Advantage payment updates, earnings, or broader risk-on rotation. Investors should not interpret this bill as a bullish catalyst for these insurers—it does not reduce their core litigation exposure. The structural winners are non-group health insurers ($ALL, $PGR, $TRV, $BRK.B) which would see reduced MSP liability, though the savings are small relative to their total claim expense.

Bill Details

Metric	Value
Bill Number	HR4056
Market Sentiment	neutral
Event Date	June 20, 2025
Affected Sectors	Healthcare, Finance
Source	View on Congress.gov →

Summary

The RAMP Act (HR4056) is an early-stage bill that would restrict the Medicare Secondary Payer private right of action to group health plans only, granting legal relief to auto, liability, workers' compensation, and no-fault insurers. The bill is referenced to two committees and has only one cosponsor, indicating a long legislative path. For the named insurers—UnitedHealth, Cigna, Humana—the bill is largely neutral as they primarily operate group health plans, which retain existing litigation exposure.

Full AI Market Analysis

The RAMP Act (HR4056), introduced June 20, 2025, by Rep. Bilirakis (R-FL) with one cosponsor, proposes amending Section 1862(b)(3)(A) of the Social Security Act to limit private causes of action under the Medicare Secondary Payer (MSP) rules exclusively to group health plans. Currently, the private right of action allows Medicare to sue non-group primary plans (auto, liability, workers' comp, no-fault) for failing to pay as primary payer. The bill would remove that threat for non-group plans, effectively lowering litigation risk for auto insurers, workers' compensation carriers, and liability carriers. There is no authorized or appropriated funding in this bill—it is a legal liability cap, not a spending measure. The money trail is avoidance of legal defense costs, settlements, and judgments for non-group health plans. Companies like Allstate ($ALL), Progressive ($PGR), Berkshire Hathaway (GEICO, $BRK.B), and Travelers ($TRV) would see reduced MSP-related litigation expenses, though the dollar impact is likely modest relative to their total claim reserves. The three insurers cited in the Congressional event details—UnitedHealth, Cigna, Humana—are primarily group health plan operators. Since the bill preserves the private right of action for group health plans, they continue to face MSP liability for their Medicare Advantage and employer plan lines. The benefit to these companies is indirect at best, stemming from a general reduction in industry legal friction. The real beneficiaries are non-group health insurers not listed in the provided data. Real market data shows $UNH at $366.27, up 35.36% over 30 days; at $287.63, up 7.83% over 30 days; at $241.41, up 39.23% over 30 days. These recent price surges are likely driven by factors other than the RAMP Act (e.g., broader healthcare policy or earnings), given the bill is in early committee stage with no scheduled markups. Timeline: The bill was referred to House Ways & Means and Energy & Commerce committees on June 20, 2025. No further action recorded through April 30, 2026. Companion bill S3816 was also introduced and referred to Senate Finance. For this 119th Congress, passage probability is low without a markup or sponsor expansion. If it advances, committee hearings and a vote on the House floor would be required, followed by Senate consideration.